AbbVie and Alphabet-backed Calico Life Sciences each committed up to $250M upfront with the option for an additional $500M each (total potential $1.5B), pooling resources for aging-related drug discovery centered in the Bay Area. AbbVie ultimately ended the 11-year collaboration in 2025.